Skip to main content
SpringerLink
Log in

Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)

  • Report on Investigational Drugs
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor growth and metastasis. Several anticancer therapies targeting VEGFR with small molecules and antibody have been currently studied in preclinical and clinical studies. This article provides a review of human monoclonal antibody tanibirumab (TTAC-0001), which specifically binds VEGFR-2 and is currently being developed in preclinical stage by PharmAbcine (Daejon, Korea).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Blume-Jensen, P. and Hunter, T., Oncogenic kinase signalling. Nature, 411, 355–365 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Carmeliet, P., Angiogenesis in life, disease and medicine. Nature, 438, 932–936 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Chu, Q. S., Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin. Biol. Ther., 9, 263–271 (2009).

    Article  PubMed  CAS  Google Scholar 

  • Ferrara, N., VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotechnol., 11, 617–624 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Ferrara, N. and Gerber, H. P., The role of vascular endothelial growth factor in angiogenesis. Acta Haematol., 106, 148–156 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Ferrara, N. and Kerbel, R. S., Angiogenesis as a therapeutic target. Nature, 438, 967–974 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1, 27–31 (1995).

    Article  PubMed  CAS  Google Scholar 

  • Gerber, H. P. and Ferrara, N., Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res., 65, 671–680 (2005).

    PubMed  CAS  Google Scholar 

  • Hicklin, D. J. and Ellis, L. M., Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol., 23, 1011–1027 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J. P., Daly, T., Wiegand, S. J., Yancopoulos, G. D., and Rudge, J. S., VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A., 99, 11393–11398 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Jussila, L. and Alitalo, K., Vascular growth factors and lymphangiogenesis. Physiol. Rev., 82, 673–700 (2002).

    PubMed  CAS  Google Scholar 

  • Karkkainen, M. J., Mäkinen, T., and Alitalo, K., Lymphatic endothelium: a new frontier of metastasis research. Nat. Cell Biol., 4, E2–E5 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Kerbel, R. S., Tumor angiogenesis: past, present and the near future. Carcinogenesis, 21, 505–515 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Rafii, S., Lyden, D., Benezra, R., Hattori, K., and Heissig, B., Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer, 2, 826–835 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Spratlin, J. L., Mulder, K. E., and Mackey, J. R., Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol., 6, 1085–1094 (2010).

    Article  PubMed  CAS  Google Scholar 

  • Spratlin, J., Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr. Oncol. Rep., 13, 97–102 (2011).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. PharmAbcine, Daejeon, 305-811, Korea

    Sang Hoon Lee

Authors
  1. Sang Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sang Hoon Lee.

Additional information

Edited by Sang-Bae Han, College of Pharmacy and Medical Research Center (CICT), Chungbuk National University, Cheongju 361-763, Korea Tel: 82-43-261-2815, E-mail: shan@chungbuk.ac.kr

Sang Hoon Lee PharmAbcine, Korea, Vice President & Co-founder

Main Research Area Angiogenesis, Cancer Biology, Signal Transduction, Oncology Drug Discovery and Development, Translational Science, Biomarkers, Small Molecule Kinase Inhibitor, Therapeutic Antibody

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, S.H. Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch. Pharm. Res. 34, 1223–1226 (2011). https://doi.org/10.1007/s12272-011-0821-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-011-0821-9

Keywords

Search

Navigation